These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 16280694

  • 1. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
    Nelson M, Arastéh K, Clotet B, Cooper DA, Henry K, Katlama C, Lalezari JP, Lazzarin A, Montaner JS, O'Hearn M, Piliero PJ, Reynes J, Trottier B, Walmsley SL, Cohen C, Eron JJ, Kuritzkes DR, Lange J, Stellbrink HJ, Delfraissy JF, Buss NE, Donatacci L, Wat C, Smiley L, Wilkinson M, Valentine A, Guimaraes D, Demasi R, Chung J, Salgo MP.
    J Acquir Immune Defic Syndr; 2005 Dec 01; 40(4):404-12. PubMed ID: 16280694
    [Abstract] [Full Text] [Related]

  • 2. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
    Reynes J, Arastéh K, Clotet B, Cohen C, Cooper DA, Delfraissy JF, Eron JJ, Henry K, Katlama C, Kuritzkes DR, Lalezari JP, Lange J, Lazzarin A, Montaner JS, Nelson M, O' Hearn M, Stellbrink HJ, Trottier B, Walmsley SL, Buss NE, Demasi R, Chung J, Donatacci L, Guimaraes D, Rowell L, Valentine A, Wilkinson M, Salgo MP.
    AIDS Patient Care STDS; 2007 Aug 01; 21(8):533-43. PubMed ID: 17711378
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A, Clotet B, Cooper D, Reynes J, Arastéh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, TORO 2 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2186-95. PubMed ID: 12773645
    [Abstract] [Full Text] [Related]

  • 4. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, TORO 1 Study Group.
    N Engl J Med; 2003 May 29; 348(22):2175-85. PubMed ID: 12637625
    [Abstract] [Full Text] [Related]

  • 5. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
    Cohen CJ, Clumeck N, Molina JM, Thompson M, Patel K, Wintfeld N, Green J.
    J Acquir Immune Defic Syndr; 2004 Sep 01; 37(1):1140-6. PubMed ID: 15319673
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
    Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.
    J Acquir Immune Defic Syndr; 2005 Dec 01; 40(4):413-21. PubMed ID: 16280695
    [Abstract] [Full Text] [Related]

  • 9. Switching from a toxicity-causing antiretroviral to enfuvirtide in patients with HIV: the SWITCH TOX study.
    Streinu-Cercel A, de Gorgolas M, Müller M, Portilla J, Rugina S, Böcher W, Staszewski S, Pulik P, Rowell L, Salgo M, Stoll M.
    HIV Clin Trials; 2008 Dec 01; 9(6):375-86. PubMed ID: 19203903
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of enfuvirtide in combination with darunavir-ritonavir and an optimized background regimen in treatment-experienced human immunodeficiency virus-infected patients: the below the level of quantification study.
    DeJesus E, Gottlieb MS, Gathe JC, Greenberg ML, Guittari CJ, Zolopa AR.
    Antimicrob Agents Chemother; 2008 Dec 01; 52(12):4315-9. PubMed ID: 18809940
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Short-term additional enfuvirtide therapy is associated with a greater immunological recovery in HIV very late presenters: a controlled pilot study.
    Bonora S, Calcagno A, Cometto C, Fontana S, Aguilar D, D'Avolio A, Gonzalez de Requena D, Maiello A, Dal Conte I, Lucchini A, Di Perri G.
    Infection; 2012 Feb 01; 40(1):69-75. PubMed ID: 22135137
    [Abstract] [Full Text] [Related]

  • 14. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J, Dusek A, DeSpirito M, Demasi RA.
    Clin Drug Investig; 2007 Feb 01; 27(7):469-79. PubMed ID: 17563127
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
    Salzberger B, Däumer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Sturmer M.
    Eur J Med Res; 2007 Mar 26; 12(3):93-102. PubMed ID: 17507306
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients.
    Viard JP, Fagard C, Chaix ML, Rouzioux C, Bouteloup V, Bentata M, de Verdière NC, Pahlavan G, Weiss L, Lévy Y, Chêne G, ANRS 123 ETOILE trial group.
    AIDS; 2009 Jul 17; 23(11):1383-8. PubMed ID: 19461505
    [Abstract] [Full Text] [Related]

  • 19. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
    Walmsley S, Henry K, Katlama C, Nelson M, Castagna A, Reynes J, Clotet B, Hui J, Salgo M, DeMasi R, Delehanty J.
    J Infect Dis; 2003 Dec 15; 188(12):1827-33. PubMed ID: 14673761
    [Abstract] [Full Text] [Related]

  • 20. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE, Workman C, Hales G, Amin J, Cooper D, Miller J, Alliance Study Group.
    Antivir Ther; 2006 Dec 15; 11(4):409-19. PubMed ID: 16856614
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.